All lobbying filings

SMITHBUCKLIN CORPORATION

Lobbying for ASTCT · Healthcare Society

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 16, 2026

Income

$70,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 7

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications OMB Uniform Guidance Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act

Medicare/Medicaid

- CMS coding and billing clarity for CAR-T therapies - CMS engagement on MS-DRG 018 for CAR-T therapies - H.R. 2491/S. 1227, the Alleviating Barriers to Care Act

Medical/Disease Research/Clinical Labs

- Labor-HHS Appropriations - CAR-T Therapy clarification - S. 4440/H.R. 3521, the Clinical Trial Modernization Act - OMB Uniform Guidance Oversight

Bills named in this filing 8

H.R. 2491
ABC Act
S. 1227
ABC Act
H.R. 5160
Stem Cell Therapeutic and Research Reauthorization Act of 2025
S. 4109
Stem Cell Therapeutic and Research Reauthorization Act of 2026
H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 932
Give Kids a Chance Act of 2025
S. 4440
Clinical Trial Modernization Act
H.R. 3521
Clinical Trial Modernization Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.